2022 World Conference on Lung Cancer (ePosters)-EP08.02-140. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

EP08.02-140. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

Back to course

Pdf Summary

This document discusses the results of a study investigating the efficacy and safety of combining savolitinib, a drug that targets the MET protein, with osimertinib, a drug that targets the EGFR protein, in patients with non-small cell lung cancer (NSCLC) who had developed resistance to osimertinib. The study aimed to identify the best methods of detecting MET-related resistance and to determine the thresholds that would indicate improved response to the combination treatment.<br /><br />The study found that patients with high levels of MET protein and/or MET gene had better outcomes with the savolitinib and osimertinib combination compared to patients with lower levels of MET. Among the subgroup of patients with high MET levels, the objective response rate was 49% and the median progression-free survival was 7.1 months. The duration of response was not fully matured but appeared to be durable.<br /><br />The safety outcomes of the combination treatment were consistent with the known profiles of the individual drugs. Common adverse events included pulmonary embolism, dyspnea, decreased neutrophil count, and pneumonia.<br /><br />The estimated prevalence of patients with NSCLC and high MET levels was 34%, indicating that MET overexpression and/or amplification is a common resistance mechanism to osimertinib.<br /><br />The study concluded that appropriate MET biomarker-based patient selection is necessary to identify the patients who are most likely to benefit from the savolitinib and osimertinib combination. Further assessment of the efficacy and safety of the combination treatment is ongoing in the SAVANNAH study and the Phase III SAFFRON study.<br /><br />Overall, the study highlights the potential of combining savolitinib and osimertinib as a treatment option for patients with EGFR-mutated NSCLC who have developed resistance to osimertinib due to MET alterations. However, further research and clinical trials are needed to confirm the findings and determine the optimal treatment strategies.

Asset Subtitle

Myung-Ju Ahn

Meta Tag

Speaker Myung-Ju Ahn

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

study

efficacy

safety

savolitinib

osimertinib

non-small cell lung cancer

resistance

MET-related resistance

combination treatment

MET overexpression